Welcome to Vor Bio
Vor Bio is a clinical-stage biotechnology company transforming the treatment of autoimmune diseases. Our goal is to bring life-changing therapies to patients worldwide who are living with serious, autoantibody-driven conditions.
We are advancing telitacicept, a novel, dual-target recombinant fusion protein that inhibits both BLyS (BAFF) and APRIL—two key cytokines involved in B cell survival and autoantibody production.
This dual-target mechanism reduces autoreactive B cells and autoantibody production, key drivers of autoimmune pathology.
In a Phase 3 clinical trial in generalized myasthenia gravis in China, telitacicept demonstrated a 4.8-point improvement in MG-ADL (Myasthenia Gravis Activities of Daily Living scale) vs. placebo at 24 weeks, the primary endpoint of the trial.
Telitacicept is approved in China for systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and generalized myasthenia gravis (gMG). A global Phase 3 clinical trial in gMG is currently underway across the United States, Europe, and South America to support potential approval in the United States and Europe.
Leadership
Jean-Paul Kress, M.D.
With the leadership of our new CEO and Chairman, Jean‑Paul Kress, M.D., and the support of a significant strategic investment, we are entering an exciting new phase—focused, well-capitalized, and driven by a commitment to improving outcomes for patients with autoimmune disease.
The Latest About Vor Bio
Press Releases
Vor Bio Announces $175 Million Private Placement
CAMBRIDGE, Mass., June 25, 2025 (GLOBE NEWSWIRE) — Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that it has entered into a securities purchase agreement for a private placement in public equity financing (the “PIPE”) that is expected to result in gross proceeds of approximately $175 million, before deducting expenses.
Vor Bio Enters into Exclusive Global License Agreement with RemeGen for Late-Stage Autoimmune Asset
CAMBRIDGE, Mass., June 25, 2025 (GLOBE NEWSWIRE) — Vor Bio, Inc. (Nasdaq: VOR) and RemeGen Co., Ltd. (HKEX: 9995, SHA: 688331) today announced entry into an exclusive license agreement granting Vor Bio global rights (excluding China, Hong Kong, Macau and Taiwan) to develop and commercialize telitacicept, a novel dual-target fusion protein approved in China for generalized myasthenia gravis (gMG), systemic lupus erythematosus (SLE), and rheumatoid arthritis (RA).